Gilead pulls Trodelvy's ac­cel­er­at­ed la­bel in blad­der can­cer af­ter drug failed con­fir­ma­to­ry study

Gilead is with­draw­ing the ac­cel­er­at­ed ap­proval for its block­buster an­ti­body-drug con­ju­gate Trodelvy for blad­der can­cer af­ter it failed to im­prove sur­vival odds for pa­tients in …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER